Adverse events of herpes zoster vaccination among adults in Saudi Arabia: A cross-sectional study
- 1Department of Pathology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia
- 2Department of Psychology, College of Social Sciences, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia
- 3College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia
Abstract
Background: The varicella-zoster virus, which causes herpes zoster upon reactivation, remains a public health concern, particularly among older adults. Although Zostavax and Shingrix are effective vaccines, monitoring adverse events remains important. Limited vaccine uptake and low public awareness in Saudi Arabia further highlight this need. This study seeks to assess the adverse events linked to herpes zoster immunization throughout the Saudi Arabian population. Methods: This cross-sectional study used a Google Form questionnaire administered from 16 September 2024–15 August 2025. Results: A total of 382 participants completed the survey. The largest age subgroup was 18–25 years (22.3%). For the first dose, 185 participants (48.4%) did not know the vaccine type, whereas 144 (37.7%) received Zostavax and 53 (13.9%) received Shingrix. Among second-dose recipients (n = 152), 85 participants (55.9%) received Zostavax, 41 (27.0%) received Shingrix, and 26 (17.1%) were uncertain of the vaccine type. The most frequently reported adverse effects after the first dose were fatigue/headache, injection-site pain, and dizziness, whereas chills, injection-site pain, and dizziness were most frequent after the second dose. No adverse effects were reported by 112 participants (29.3%) after the first dose and 28 (18.4%) after the second dose. Participants who received Zostavax reported significantly higher self-reported severity scores than those who received Shingrix after both the first dose (p = 0.003) and the second dose (p < 0.001). Conclusion: Self-reported symptom severity was higher among participants with chronic disease and varied significantly by age after the first dose. The most commonly reported symptom duration was 1–2 days. No significant gender differences were observed. In unadjusted analyses, participants who reported receiving Zostavax had higher self-reported severity scores than those reporting Shingrix.
Related
- Reported adverse events following monovalent varicella vaccination in children aged 1–12 years: a VAERS disproportionality analysis, 1995-2026
- PÚRPURA TROMBOCITOPENICA TROMBÓTICA ASSOCIADO A DOENÇA DO TECIDO CONJUNTIVO APÓS TRATAMENTO PARA HERPES ZOSTER COM ACICLOVIR
- Immune checkpoint inhibitors and the inflammatory dysregulation: decoding cutaneous and gastrointestinal immune-related adverse events for the allergist and immunologist
- 1085 Educational intervention to increase utilization of ICD-10 codes for immune-related adverse events: a quality improvement initiative
- Relationship between autistic traits, emotional symptoms and adverse life events in Chinese adolescents: mediating effects of resilience
BibTeX
@article{aldali2026adverse,
title = {{Adverse events of herpes zoster vaccination among adults in Saudi Arabia: A cross-sectional study}},
author = {Jehad Aldali and Emadeldin Elsokkary and Ghadah Alnajdi and Marwa Maghrabi and Ruba Subh and Ghala Alakkasi and Sara Alhanshi Yati and Meshal Alzakari},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0360528},
url = {https://doi.org/10.1371/journal.pone.0360528},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Adverse events of herpes zoster vaccination among adults in Saudi Arabia: A cross-sectional study
AU - Jehad Aldali
AU - Emadeldin Elsokkary
AU - Ghadah Alnajdi
AU - Marwa Maghrabi
AU - Ruba Subh
AU - Ghala Alakkasi
AU - Sara Alhanshi Yati
AU - Meshal Alzakari
PY - 2026
DA - 2026/10/27
JO - PLOS One
DO - 10.1371/journal.pone.0360528
UR - https://doi.org/10.1371/journal.pone.0360528
AB - Background: The varicella-zoster virus, which causes herpes zoster upon reactivation, remains a public health concern, particularly among older adults. Although Zostavax and Shingrix are effective vaccines, monitoring adverse events remains important. Limited vaccine uptake and low public awareness in Saudi Arabia further highlight this need. This study seeks to assess the adverse events linked to herpes zoster immunization throughout the Saudi Arabian population. Methods: This cross-sectional study used a Google Form questionnaire administered from 16 September 2024–15 August 2025. Results: A total of 382 participants completed the survey. The largest age subgroup was 18–25 years (22.3%). For the first dose, 185 participants (48.4%) did not know the vaccine type, whereas 144 (37.7%) received Zostavax and 53 (13.9%) received Shingrix. Among second-dose recipients (n = 152), 85 participants (55.9%) received Zostavax, 41 (27.0%) received Shingrix, and 26 (17.1%) were uncertain of the vaccine type. The most frequently reported adverse effects after the first dose were fatigue/headache, injection-site pain, and dizziness, whereas chills, injection-site pain, and dizziness were most frequent after the second dose. No adverse effects were reported by 112 participants (29.3%) after the first dose and 28 (18.4%) after the second dose. Participants who received Zostavax reported significantly higher self-reported severity scores than those who received Shingrix after both the first dose (p = 0.003) and the second dose (p < 0.001). Conclusion: Self-reported symptom severity was higher among participants with chronic disease and varied significantly by age after the first dose. The most commonly reported symptom duration was 1–2 days. No significant gender differences were observed. In unadjusted analyses, participants who reported receiving Zostavax had higher self-reported severity scores than those reporting Shingrix.
SN - 1932-6203
ER -